Business Description
Rein Therapeutics is a US-based drug development company working on treatments for rare lung and fibrosis diseases that currently have few or no effective options. Its most advanced programs include LTI-03, a peptide being tested in clinical trials for idiopathic pulmonary fibrosis, and LTI-01, which has already completed early-stage trials for a serious fluid buildup condition affecting the lungs. The company also has several earlier-stage programs targeting cystic fibrosis and broader fibrosis conditions. Founded in 2001 and based in Austin, Texas, Rein Therapeutics was previously known as Aileron Therapeutics before adopting its current name in 2007.
